PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
01-Oct-2024 PharmaSGP Holding SE has purchased 477,701 own shares through its public share repurchase offer PharmaSGP Holding SE
30-Sep-2024 Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities Biophytis
30-Sep-2024 Xlife Sciences AG enables international co-investors to enter the stock and is planning a dual listing on the London Stock Exchange Group (LSEG) Xlife Sciences AG
30-Sep-2024 Gerresheimer AG: Adjustment of growth guidance for 2024 and 2025 Gerresheimer AG
30-Sep-2024 Medacta Hosts Inaugural Capital Markets Day, Showcasing Responsible Innovation and Effective Growth Strategy Medacta Group SA
30-Sep-2024 Modern Dental Group Shared the Technological Innovation in Dentistry Along the Development of New Quality Productive Forces in CCB International Forum Modern Dental Group Limited
30-Sep-2024 Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz) Formycon AG
27-Sep-2024 DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update Nyxoah SA.
27-Sep-2024 FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz) Formycon AG
27-Sep-2024 Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Sanofi
27-Sep-2024 Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster Orion
27-Sep-2024 Original-Research: Sernova Corp (von First Berlin Equity Research GmbH) Sernova Corp
27-Sep-2024 Share price target 12.50 euros: Annual General Meeting supports SYNBIOTIC's growth plans with over 99 percent approval SYNBIOTIC SE
27-Sep-2024 Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases Formycon AG
26-Sep-2024 Affluent Medical SA: H1 2024 RESULTS - Major advances in all three programs - Several strategic agreements signed with the world medtech leader in cardiology - Extension of financial runway Affluent Medical SA
26-Sep-2024 SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU” SCHOTT Pharma AG & Co. KGaA
26-Sep-2024 Gerresheimer, Stevanato Group and SCHOTT Pharma Announce Strategic Industry “Alliance for RTU” Gerresheimer AG
26-Sep-2024 Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 ABIVAX
26-Sep-2024 Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies Evotec SE
25-Sep-2024 Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model ABIVAX